Lantern Pharma
LTRN
33 hedge funds and large institutions have $2.87M invested in Lantern Pharma in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
0% more funds holding
Funds holding: 33 → 33 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
1.64% less ownership
Funds ownership: 20.39% → 18.75% (-1.6%)
58% less capital invested
Capital invested by funds: $6.91M → $2.87M (-$4.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$69.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.7K |
| 3 |
WIM
Westside Investment Management
Santa Monica,
California
|
+$39.6K |
| 4 |
Renaissance Technologies
New York
|
+$15.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BIOS Capital Management
Fort Worth,
Texas
|
-$406K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$99.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$87.3K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$29.8K |
| 5 |
Bank of New York Mellon
New York
|
-$14.5K |
LTRN Hedge Fund Activity: Q1 2026 in Review
33 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q1 2026, worth a combined $2.87M — down 58% from $6.91M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LTRN positions and 3 closed out — a net gain of 2 holders — while 9 added to existing stakes and 9 trimmed.
The largest buyer was CM Management, adding an estimated $69.9K. The largest seller was BIOS Capital Management, cutting an estimated $406K.
- 33 institutional investors held Lantern Pharma (LTRN) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $2.87M of Lantern Pharma stock for Q1 2026, down 58% quarter-over-quarter.
- 5 funds opened new Lantern Pharma positions in Q1 2026 and 3 closed out, a net change of +2 holders.
- The largest Lantern Pharma buyer in Q1 2026 was CM Management, an estimated $69.9K added.
- The largest Lantern Pharma seller in Q1 2026 was BIOS Capital Management, an estimated $406K sold.
Based on aggregated 13F filings for Q1 2026.